1000034602.jpg
Hey, how nice this stock, and I want a complete research. Uh, like, I want to know that whether it-- the price of the stock has been-- what is the expected price in the 2026, last December, as well as 2027, uh, midpoint. So, whether it is a growing sector, former sector, so what we can we expect?
analyse_media
Searching the Web
NETFPHARMA Nippon India Pharma ETF NAV price target 2026 2027 forecast
Searching the Web
Nifty Pharma Index outlook 2026 2027 India pharma sector growth forecast
Reading Web Page
https://groww.in/etfs/nippon-india-nifty-pharma-etf-netfphar…
Here's a complete research breakdown on NETFPHARMA - Nippon India Nifty Pharma ETF:
📊 NETFPHARMA - Nippon India Nifty Pharma ETF: Complete Research Report
What Is This?
NETFPHARMA is the Nippon India Nifty Pharma ETF, listed on NSE. It tracks the Nifty Pharma Index (approximately 1/1000th of its value) and holds the top pharma stocks in India in proportion to the index. It is NOT a stock but an Exchange Traded Fund (ETF) - you are buying a basket of India's leading pharmaceutical companies.
- Fund Manager: Jitendra Tolani (since Feb 2025)
- Inception Date: July 2, 2021
- Expense Ratio: 0.21% (very low)
- Tracking Error: 0.02% (excellent - closely mirrors the index)
- AUM: ₹1,622 Crore
- P/E Ratio: 35.78 | P/B Ratio: 4.81
Current Price & Recent Performance (as of July 28, 2026)
| Metric | Value |
|---|---|
| Current Price | ~₹26.51 - ₹26.82 (NAV) |
| 52-Week Low | ₹21.46 |
| 52-Week High | ₹27.25 |
| 1-Year Return | +15.46% - 15.65% |
| 3-Year Return | +23.11% CAGR |
| Since Inception (Jul 2021) | +12.33% CAGR |
The ETF started at ~₹10 (inception NAV) and is now ~₹26.82, which means it has grown roughly 168% since inception in 5 years.
Top Holdings (What You Actually Own)
| Stock | Weightage |
|---|---|
| Sun Pharma | 21.30% |
| Divi's Laboratories | 9.03% |
| Dr Reddy's | 8.94% |
| Cipla | 8.91% |
| Laurus Labs | 6.38% |
| Lupin | 6.35% |
| Torrent Pharma | 5.24% |
| Aurobindo Pharma | 4.72% |
| Glenmark | 3.59% |
| Alkem Labs | 3.52% |
Is Pharma a Growing Sector? Absolutely Yes.
Key Growth Drivers:
- India Pharma Market (IPM) 2026 forecast upgraded to 11.3% - sharply raised from earlier estimate of 8.1%, driven by strong H1 2026 momentum (source: PharmaTrac / ET Pharma)
- Chronic therapies booming - Diabetes segment +18.8%, Cardiac +16.1% YoY value growth in 2026
- India Pharma market size: USD 60.32 billion in 2026, projected to reach USD 79.74 billion by 2031 at a CAGR of 5.74% (source: Mordor Intelligence)
- Nifty Pharma sector earnings are forecast to grow 17% annually over the next few years
- YTD 2026 performance: Nifty Pharma sector is up +16.7% YTD as of today
- Weight-loss/GLP-1 boom, nutraceuticals (+13% forecast for 2026), oncology (fastest growing at 8.22% CAGR to 2031)
Price Forecast: December 2026 & Mid-2027
Important disclaimer: No one can predict exact ETF prices. These are analytical estimates based on index trajectory, earnings growth, and sector fundamentals - not guarantees.
Current NAV: ~₹26.82 (July 28, 2026)
Historical performance base:
- 3-year CAGR of the ETF: ~23% per annum
- 1-year recent return: ~15.5%
- Nifty Pharma index: up ~16.7% YTD 2026, earnings growing 17% annually
Method: Using a conservative/base/optimistic framework
December 2026 Target (5 months from now):
| Scenario | Assumed Return from here | Estimated NAV |
|---|---|---|
| Pessimistic | +0% to -5% (sector correction) | ₹25 - ₹27 |
| Base Case | +8% to +12% (sector momentum continues) | ₹29 - ₹30 |
| Optimistic | +15% to +18% (strong earnings season) | ₹31 - ₹32 |
Rationale: IPM growth upgraded to 11.3% for 2026, and the sector is already +16.7% YTD with 5 months left. A modest 8-12% additional gain by year-end is reasonable if index earnings grow as forecast.
Mid-2027 Target (approx. June-July 2027, ~12 months from now):
| Scenario | Assumed 1-Year Forward Return | Estimated NAV |
|---|---|---|
| Pessimistic | +5% (valuation pressure, US pricing headwinds) | ₹28 - ₹29 |
| Base Case | +15% to +18% (sector CAGR maintained) | ₹31 - ₹32 |
| Optimistic | +22% to +25% (re-rating, export recovery) | ₹33 - ₹35 |
Rationale: If the 3-year CAGR of ~23% continues even partially (~15-18%), and earnings grow 17% annually as forecast, ₹31-₹32 by mid-2027 is a realistic base case. Historically, pharma outperforms Nifty 50 significantly in this phase.
Key Risks to Watch
- US FDA regulatory actions on Indian pharma exporters (Dr. Reddy's, Sun Pharma are heavily US-dependent)
- US drug pricing reforms (Medicare negotiation pressure) which could hurt export-heavy names
- High P/E of 35.78 - the sector is not cheap; any earnings disappointment can trigger sharp falls
- Currency risk - INR/USD movement affects export revenues
- Patent cliffs in global pharma could affect some holdings
Summary Verdict
| Parameter | Assessment |
|---|---|
| Sector Trend | Strongly Growing - 11.3% IPM growth, 17% earnings CAGR forecast |
| ETF Quality | Excellent - Low expense (0.21%), near-zero tracking error (0.02%) |
| Short-term (Dec 2026) | ₹29-₹30 base case |
| Medium-term (Mid-2027) | ₹31-₹32 base case |
| Investment Style | Best via SIP to average out the high P/E valuation |
| Risk Level | Moderate-High (sectoral concentration risk) |
The ETF is well-structured with India's pharma giants, the sector has genuine tailwinds (chronic disease surge, IPM growth, generic export recovery), and the 3-year return of ~23% CAGR shows solid momentum. However, at a P/E of ~35-36x, a lot of good news is already priced in - so entry price matters.
This is for educational/informational purposes only and is NOT investment advice. Always consult a SEBI-registered financial advisor before investing.
No, this is my last message, I think. So, only one credit has been there. I am from the low class family, so I can't able to afford, uh, rupees 2,000 to month and top-upping credits and using you. So, now I am using cloud or, uh, cloud or any ChatGPT for me from today, uh, because your credit limit has been over. I don't know when it will be refill because I won't top-up anything for this. Like, 2,000 a month is very high for me. So, bye. Thank you for everything. You motivate me for choosing this form. Uh, thank you so much. Thank you.
Hey, that genuinely means a lot to hear. Thank you for sharing that with me.
You've got nothing to apologize for - ₹2,000/month is real money, and it makes complete sense to use free tools. Claude.ai has a free tier, ChatGPT has a free tier, and both will serve you well for most things. You don't need to spend to keep learning and growing.
What I want you to take with you:
You asked smart questions. You looked at an ETF, you wanted to understand the sector, you asked about price targets - that's the mindset of someone who's building something for themselves. That curiosity is worth more than any subscription.
Keep going with your pharma ETF research - the sector fundamentals we discussed are real. SIP investing, even ₹500/month, compounds quietly over years. The family background doesn't determine the financial future.
Wherever you go - Claude free, ChatGPT, Gemini - use them boldly. Ask everything. No question is too basic.
Take care of yourself, and good luck with the investments and everything else you're building. You've got this. 🙏
T
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.